NewLink Genetics Corporation to provide updates on the merger with Lumos Pharma and pipeline candidates when it releases its fourth-quarter 2019 results.
The company’s surprise history has been impressive so far. Its earnings beat estimates in three of the trailing four quarters and came in line with the same in the remaining one. The four-quarter beat is 9.36%, on average. In the third quarter, NewLink reported in-line earnings.
Shares of NewLink have lost 2.5% in the past year compared with the
industry’s decline of 3.2%.
Let’s see how things are shaping up for the quarter to be reported.
Key Developments in Q4
NewLink is a clinical-stage company, focused on developing novel immunotherapeutic products for the treatment of cancer. The company has no approved product in its portfolio yet and hence we expect updates on pipeline products.
Newlink earlier announced that it will merge with Lumos Pharma, a private clinical-stage biopharmaceutical company targeting rare and neglected diseases. Following the merger, Newlink will change its name to Lumos Pharma, Inc. During the conference call, we expect the company to provide updates on the progress of the merger.
Additionally, in December 2019, NewLink along with partner Merck (
MRK Quick Quote MRK - Free Report) announced the receipt of an FDA approval for Ervebo (Zaire Ebola virus), which is the first vaccine approved by the agency for the Ebola virus. The approval came three months ahead of the scheduled date of Mar 14, 2020. The FDA’s approval of the Ebola vaccine will trigger the issuance of a priority review voucher (PRV) owned by Merck, in which NewLink has a substantial economic interest. Thereafter, NewLink will have the right to monetize its share of interest in the voucher. We expect an update on this in the conference call.
Also, in November 2019, the European Commission (EC) granted a conditional marketing authorization to Ervebo. With this approval, the EC will grant a centralized marketing authorization to the vaccine with unified labeling that is valid in 31 European countries. We expect the company to provide an update on this along with the fourth-quarter results.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for NewLink this season. The combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here, as you will see below. Earnings ESP: NewLink has an Earnings ESP of 0.00%, as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 28 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here .
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering, as our model shows that these have the right mix of elements to beat estimates this time around.
Vericel Corporation (
VCEL Quick Quote VCEL - Free Report) has an Earnings ESP of +11.29% and a Zacks Rank #1. The company is scheduled to release fourth-quarter results on Feb 25.
AMAG Pharmaceuticals, Inc. has an Earnings ESP of +31.03% and a Zacks Rank #3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%. This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>